Search CommunityWalk:
Create_a_map_small
Mymaps_small



Blank

Kempbio, Inc

Address:
4539 Metropolitan Ct.
--
Frederick, MD 21704, USA
1-301-644-3922

Category: BioManufacturing; Research Services & Supplies; Suppliers (CRO)

Used in the following map:

Maryland Biotech Industry Map

Kempbio, Inc. is a CRO company focused on protein expression. It was founded in January 2009, with an expertise in baculoviral and mammalian expression systems with exceptional customer service to provide its customers with the best possible outsourcing experience.

Kempbio has developed a robust system for the transient expression of recombinant proteins using the human cell line, HEK-293. This system provides a mechanism for the rapid expression of milligram to gram quantities of recombinant proteins with authentic human post-translational processing. Its optimized serum-free media, cell line and transfection reagent combine to provide the highest quality and quantity of protein expression available. The company provides protein purification services for both affinity-tagged and untagged proteins.

Kempbio's baculovirus expression service offers a complete line of services related to the expression of recombinant proteins using the baculovirus expression system. Its baculovirus expression service include: production, purification and characterization of recombinant baculovirus clones in addition to scale-up for protein expression. The company also provides GLP cell banking services. It has experience in producing cell banks for non-recombinant and recombinant mammalian and insect cell lines. Each bank is tested for mycoplasma contamination, sterility and viability on thaw.

Kempbio's mammalian cell culture offers expanded services for the optimization, scale-up and production of cell culture derived materials. Its services include: the production of secreted and non-secreted proteins, protein purification and the isolation of cellular sub-fractions (i.e. membranes and nuclei) from recombinant and non-recombinant cell lines. The company has worked with Human Monocytic Leukemia, 293 (Recombinant), Human Colon Adenocarcinoma, CHO (Recombinant), Hybridoma (Murine), EBV Transformed Cells, Heterohybridoma (Mouse-Human), rMyeloma, Myeloma (Recombinant), Neuroblastoma, Primary Mouse Embryo Fibroblasts, etc.

Kempbio has signed a license agreement with Polyplus-transfection SA for the transfection of cells used for the production of recombinant proteins.